Health Care Technology
Company Overview of Caprion Proteomics, Inc.
Caprion Proteomics, Inc. provides proteomics discovery technologies and services to pharmaceutical industries. It offers CellCarta Discovery Platform that enables the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that reduces risk and enhances clinical development productivity and decision making in pharmaceutical research. The company’s platform is also used to discover novel and insights for targeting and treating cancer and infectious diseases. It offers on-going programs to identify novel tumor cell-surface targets for cancer antibody therapy. Caprion Proteomics, Inc. was formerly known as Caprion Proteomics GP and changed its ...
Montreal, QC H4S 2C8
Founded in 2007
Key Executives for Caprion Proteomics, Inc.
Vice President of Finance
Chief Business Officer and Senior Vice-President
Senior Vice-President of Corporate Development and Diagnostics
Vice President of Biomarker Discovery and Diagnostics
Compensation as of Fiscal Year 2014.
Caprion Proteomics, Inc. Key Developments
Caprion Proteomics Announces Study Results on Development of Blood-Based Diagnostic for Lung Cancer Yields Publication in Science Translational Medicine
Oct 16 13
Caprion Proteomics announced the results of a major study conducted by Indi (Integrated Diagnostics) which suggests that quantification of a combination of blood proteins can accurately distinguish between benign lung nodules and early-stage lung cancer. The study, which was published in Science Translational Medicine (STM) and includes several Caprion scientists as co-authors, indicates that when the relative concentrations of this group of proteins (or 'classifier') is combined, the classifier result is correct more than 90% of the time in diagnosing benign lung nodules. This multiple protein classifier uses a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec). The laboratory-based analytical method, combined with sophisticated bioinformatics and systems-biology approaches allowed the researchers to assess the diagnostic power of 371 potential lung cancer biomarkers in millions of different combinations before settling on the diagnostic classifier (set of biomarkers) that these data indicate is most effective.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries